R R

What Is the Success Rate of Low-Dose Atropine for Myopia Control?

Low-dose atropine is a pharmacological intervention designed to slow the progression of myopia (nearsightedness) in children. Unlike standard atropine used for pupil dilation, low-dose versions typically 0.01 percent, 0.025 percent, or 0.05 percent are formulated to minimize side effects while still inhibiting the elongation of the eyeball. The primary goal is not to "fix" existing nearsightedness, but to reduce the rate at which the eye grows too long, which is the physical cause of high myopia and its associated risks later in life, such as retinal detachment and glaucoma.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is the Success Rate of Low-Dose Atropine for Myopia Control?

Low-dose atropine is a pharmacological intervention designed to slow the progression of myopia (nearsightedness) in children. Unlike standard atropine used for pupil dilation, low-dose versions typically 0.01 percent, 0.025 percent, or 0.05 percent are formulated to minimize side effects while still inhibiting the elongation of the eyeball. The primary goal is not to "fix" existing nearsightedness, but to reduce the rate at which the eye grows too long, which is the physical cause of high myopia and its associated risks later in life, such as retinal detachment and glaucoma.

read more about low-dose atropine myopia control success rate ...

Copy this HTML:

Copy HTML Copied!

Efficacy and Diopter Reduction Statistics

The success of atropine is measured by its ability to reduce the "creep" of a child's prescription over time. Clinical data from 2026 indicates that low-dose atropine can reduce myopia progression by 30 percent to 60 percent compared to children wearing standard glasses alone. In terms of diopter reduction, a child who might typically progress by -1.00 diopter per year may only see a change of -0.40 to -0.60 diopters when using the drops. The 0.05 percent concentration has shown the highest efficacy in recent trials, often performing significantly better than the 0.01 percent dose in high-progression candidates.

Success Rates by Concentration and Age

Success rates vary depending on the concentration used and the age at which the child begins treatment. Studies show that roughly 80 percent of children respond positively to low-dose atropine therapy. However, about 10 percent to 15 percent are considered "non-responders," meaning their eyes continue to elongate at a rapid pace despite the medication. For these cases, 2026 protocols often suggest a "combination therapy" approach, pairing atropine with specialized peripheral defocus glasses or Ortho-K lenses to achieve better control of the eye's axial length.

Side Effects and Patient Comfort Data

One of the primary reasons for the shift toward "low-dose" formulas is the dramatic reduction in side effects. At the 0.01 percent concentration, less than 5 percent of children report significant light sensitivity or blurred near vision. As the concentration increases to 0.05 percent, the incidence of mild pupil dilation and "near blur" increases to approximately 10 percent to 15 percent. Fortunately, most children adapt quickly, and the use of photochromic (transition) lenses or a slight increase in reading distance typically resolves any discomfort without requiring the child to stop the medication.

Long-Term "Rebound" Effect Data

A critical factor in the success of atropine is how the eye reacts when the treatment is eventually stopped. Early data on higher concentrations showed a "rebound" effect where the eye grew rapidly once the drops were discontinued. Current 2026 guidelines emphasize a gradual tapering of the dose rather than an abrupt stop. Statistics show that children who are tapered off the medication over 6 to 12 months maintain their treatment gains much more effectively than those who stop suddenly, with less than 10 percent experiencing a significant surge in myopia progression post-treatment.

FAQs on Low-Dose Atropine Success

Is 0.01% or 0.05% better?

While 0.01 percent has the fewest side effects, 2026 data from the LAMP study suggests that 0.05 percent is nearly twice as effective at slowing axial elongation. Most pediatric eye doctors now start with a concentration based on the child's current rate of progression rather than a "one size fits all" 0.01 percent approach.

Will my child still need glasses?

Yes. Atropine slows the worsening of vision, but it does not correct the existing blurry vision. Your child will still need to wear their glasses or contact lenses to see clearly during the day while using the drops at night to control the eye's growth.

How long does the treatment last?

Most children stay on atropine drops for at least two years. After the initial two-year period, the doctor will evaluate the rate of progression. If the eye has stabilized, they may begin a tapering process, but many children remain on a maintenance dose until their late teens when eye growth naturally slows down.

When to Discuss Atropine with a Pediatric Optometrist

If your child’s prescription is increasing by more than -0.50 diopters every six to twelve months, it is time to discuss myopia management. Early intervention is the key to success; every diopter of nearsightedness prevented reduces the lifetime risk of vision-threatening conditions. Your doctor will use an axial length master (optical biometry) to measure the eye's growth in millimeters, which provides the most accurate data to determine if the atropine success rate is meeting your child's specific needs.

References

https://www.aao.org/eye-health/tips-prevention/atropine-for-nearsightedness
https://pubmed.ncbi.nlm.nih.gov/30590009/
https://www.myopiaprofile.com/atropine-for-myopia-control-the-evidence/